Viatris (VTRS) Cash from Operations (2019 - 2026)
Viatris' (VTRS) quarterly Cash from Operations came in at 388300000.0 in Q1 2026, down 27.49% year-on-year from 535500000.0 in Q1 2025, and down 52.4% quarter-over-quarter from 815800000.0 in Q4 2025.
Viatris (VTRS) Cash from Operations (2019 - 2026) Analysis & Trends
Viatris' Cash from Operations history runs 8 years deep, the most recent figure standing at 388300000.0 for Q1 2026.
- On a quarterly basis, Cash from Operations fell 27.49% year-over-year to 388300000.0 in Q1 2026; TTM through Mar 2026 was 2168700000.0, a 2.48% decrease from a year earlier, with the FY2025 full-year figure at 2315900000.0, up 0.56% from the prior year.
- Cash from Operations declined to 388300000.0 in Q1 2026 per VTRS's latest filing, from 815800000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 1138500000.0 in Q1 2022 and bottomed at 189000000.0 in Q4 2022.
- The 5-year median for Cash from Operations is 614600000.0 (2024), against an average of 641535294.12.
- Across the five-year window, Cash from Operations sank 63.87% in 2022 and surged 200.79% in 2023, its largest moves.
- Year by year, Cash from Operations stood at 189000000.0 in 2022, then jumped by 200.79% to 568500000.0 in 2023, then declined by 15.09% to 482700000.0 in 2024, then soared by 69.01% to 815800000.0 in 2025, then slumped by 52.4% to 388300000.0 in 2026.
- Per Business Quant, the three latest VTRS Cash from Operations figures stand at 388300000.0 (Q1 2026), 815800000.0 (Q4 2025), and 744900000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -40.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 401.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 463.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 388.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 145.80 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 11.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 388.30 Mn |
| Mar 31, 2026 | 388.30 Mn |
| Dec 31, 2025 | 815.80 Mn |
| Dec 31, 2025 | 815.80 Mn |
| Sep 30, 2025 | 744.90 Mn |
| Sep 30, 2025 | 744.90 Mn |
| Jun 30, 2025 | 219.70 Mn |
| Jun 30, 2025 | 219.70 Mn |
| Mar 31, 2025 | 535.50 Mn |
| Mar 31, 2025 | 535.50 Mn |
| Dec 31, 2024 | 482.70 Mn |
| Dec 31, 2024 | 482.70 Mn |
| Sep 30, 2024 | 826.50 Mn |
| Sep 30, 2024 | 826.50 Mn |
| Jun 30, 2024 | 379.10 Mn |
| Jun 30, 2024 | 379.10 Mn |
| Mar 31, 2024 | 614.60 Mn |
| Mar 31, 2024 | 614.60 Mn |
| Dec 31, 2023 | 568.50 Mn |
| Dec 31, 2023 | 568.50 Mn |